Outcome and Complications After Implantable Cardioverter Defibrillator Therapy in Hypertrophic Cardiomyopathy-Reference-Cited by-同舟云学术

Outcome and Complications After Implantable Cardioverter Defibrillator Therapy in Hypertrophic Cardiomyopathy

Published:2012-09 Issue:5 Volume:5 Page:552-559
ISSN:1941-3289
Container-title:Circulation: Heart Failure
language:en
Short-container-title:Circ Heart Fail

Author:

Schinkel Arend F.L.¹,Vriesendorp Pieter A.¹,Sijbrands Eric J.G.¹,Jordaens Luc J.L.M.¹,ten Cate Folkert J.¹,Michels Michelle¹

Affiliation:

1. From the Department of Cardiology, Thoraxcenter (A.F.L.S., P.A.V., L.J.L.M.J., F.J.T.C., M.M.) and Department of Internal Medicine, Section of Pharmacology, Vascular and Metabolic Diseases (A.F.L.S., E.J.G.S.), Erasmus MC, Rotterdam, The Netherlands.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine

Reference34 articles.

1. Hypertrophic Cardiomyopathy

2. Sudden Death in Young Athletes

3. Cardiac Arrest during Long-Distance Running Races

4. Hypertrophic Cardiomyopathy: Role of the Implantable Cardioverter-Defibrillator

5. Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy

Cited by 145 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Candidacy and long-term outcomes of subcutaneous implantable cardioverter-defibrillators in current practice in patients with hypertrophic cardiomyopathy;International Journal of Cardiology;2024-08

2. The Paradigm of Sudden Death Prevention in Hypertrophic Cardiomyopathy;The American Journal of Cardiology;2024-02

3. The challenge of risk stratification in hypertrophic cardiomyopathy: Clinical, genetic and imaging insights from a quaternary referral centre;International Journal of Cardiology;2024-01

4. Complications of Implantable Cardioverter Defibrillator and Their Potential Risk Factors in Patients with Hypertrophic Cardiomyopathy;Cardiology Research and Practice;2023-11-13

5. Assessment of late gadolinium enhancement in hypertrophic cardiomyopathy improves risk stratification based on current guidelines;European Heart Journal;2023-10-05